ACELYRIN, Inc.
acelyrin.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q1 FY2025 10-Q, filed May 14, 2025. Its latest SEC filing is a 15-12G from Jun 9, 2025.
10-Q for Q1 FY2025, filed May 14, 2025
Sources
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops lonigutamab, an antibody treatment candidate for thyroid eye disease, for patients with the condition.
How Were They Changing?
Since the FY2024 annual report
-
May 21, 2025
Alumis completed its acquisition of ACELYRIN
ACELYRIN became a wholly owned subsidiary of Alumis.
Sources
8-K, filed May 21, 2025
As described in the Introductory Note, on May 21, 2025, the Merger was completed. Upon the consummation of the Merger, ACELYRIN became a…View ↗
-
Apr 21, 2025
ACELYRIN and Alumis amended the merger terms
The amendment set the exchange at 0.4814 Alumis shares for each ACELYRIN share.
Sources
8-K, filed Apr 21, 2025
On April 20, 2025, ACELYRIN, Alumis and Merger Sub entered into that certain Amendment to the Agreement and Plan of Merger (the…View ↗
Loading...
Comments
